Table 4.

Results of univariate survival analysis (long-rank test) for overall survival

	Entire cohort (p)/hazard ratio 95% CI	Pilocytic astrocytomas (p)/hazard ratio 95% CI	Diffusely infiltrating astrocytomas (p)/hazard ratio 95% CI
Histological grade (I vs II vs III/IV)	< 0.001/8.1 [2.5, 27.1]	-	0.028/3.8 [0.8–17.8]
Age (< 8.4 vs ≥ 8.5)	0.479/0.7 [0.2, 2.0]	0.812/1.01 [0.1–7.5]	0.949/0.97 [0.3–2.8]
Gender (1: male, 2: female)	0.389/1.6 [0.5, 4.6]	0.071/1.3 [0.2, 7.1]	0.371/1.5 [0.5–4.5]
Surgical excision (complete/partial)	< 0.001/106.7 [1.4, 7990.8]	–	0.393/1.3 [0.7–2.7]
Chemotherapy (+ / −)	0.526/1.4 [0.5, 4.1]	0.75/ 0.7 [0.08–6.1]	0.969/0.9 [0.3–2.8]
Radiation (+ / −)	0.026/3.2 [1.0, 10.5]	0.661/0.3 [0.002–49.6]	0.029/3.3 [0.9–11.6]
Ki-67 expression (%) (< 3 vs ≥ 3)	0.021/6.9 [0.9, 53.2]	0.077/0.3 [0.02–2.8]	0.723/1.3 [0.2–10.4]
p53 expression (%) (< 5 vs ≥ 5)	0.057/3.6 [0.8, 16.4]	0.003/33.3 [2.7–410.6]	0.993/0.9 [0.2–4.4]
H3K27M expression (positive vs negative)	< 0.001/0.15 [0.05, 0.43]	–	0.107/2.1 [0.7–6.2]
H3K9me3 H-score (< 270 vs ≥ 270)	0.05/2.7 [0.9, 8.5]	0.077/0.3 [0.02–5.7]	0.03/2.8 [0.9–9.1]
H3K27me3 H-score (< 100 vs ≥ 100)	0.267/0.6 [0.2, 1.6]	0.057/0.3 [0.05–2.4]	0.947/1.03 [0.4–2.9]
H4K20me3 H-score (< 250 vs ≥ 250)	0.536/1.4 [0.5, 3.9]	0.465/1.1 [0.03–42.4]	0.44/0.7 [0.2–2.0]
H3K4me3 H-score (< 190 vs ≥ 190)	0.136/2.2 [0.7, 7.0]	0.061/2.1 [0.2–20.2]	0.021/3.0 [0.9–9.5]
H3K36me3 H-score (< 300 vs ≥ 300)	0.991/0.9 [0.4, 2.8]	0.537/3.4 [0.4–29.4]	0.404/1.4 [0.5–3.9]
SETDB1 H-score (< 120 vs ≥ 120)	0.644/1.2 [0.4, 3.4]	0.858/7.1 [0.8–60.3]	0.32/1.5 [0.6–4.4]
SUV39H1 H-score (< 30 vs ≥ 30)	0.022/0.3 [0.1, 0.9]	0.493/0.3 [0.05–1.9]	0.089/0.5 [0.2–1.3]
EZH2 H-score (< 0.5 vs ≥ 0.5)	0.243/0.5 [0.1, 1.8]	0.091/0.2 [0.02–2.3]	0.253/0.5 [0.2–1.9]
MLL2 H-score (< 15 vs ≥ 15)	0.048/2.8 [0.9, 8.9]	0.641/0.4 [0.03–5.4]	0.668/0.8 [0.3–2.6]
SETD2 H-score (< 190 v ≥ 190)	0.261/1.7 [0.6, 5.2]	0.359/0.3 [0.02–4.3]	0.547/1.3 [0.4–3.8]